摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-哌啶基)乙酮盐酸盐 | 89895-06-7

中文名称
1-(4-哌啶基)乙酮盐酸盐
中文别名
1-(哌啶-4-基)乙酮盐酸盐
英文名称
1-(piperidin-4-yl)ethan-1-one hydrochloride
英文别名
4-acetylpiperidine hydrochloride;1-(Piperidin-4-yl)ethanone hydrochloride;1-piperidin-4-ylethanone;hydrochloride
1-(4-哌啶基)乙酮盐酸盐化学式
CAS
89895-06-7
化学式
C7H13NO*ClH
mdl
——
分子量
163.647
InChiKey
BWWUETLSKAKGGM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    151-158°C
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    -3.45
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    33.7
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:135b848665c056617086dd9724bb38ed
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-(Piperidin-4-yl)ethanone, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-(Piperidin-4-yl)ethanone, HCl
CAS number: 89895-06-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H13NO.ClH
Molecular weight: 163.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    1-(4-哌啶基)乙酮盐酸盐四(三苯基膦)钯sodium methylatepotassium carbonatecaesium carbonate 作用下, 以 四氢呋喃1,4-二氧六环乙醇乙腈 为溶剂, 反应 62.0h, 生成 6-(2-amino-6-(1-ethylpiperidin-4-yl)pyrimidin-4-yl)-3'-fluoro-5-methoxy-[2,4'-bipyridin]-2'-amine
    参考文献:
    名称:
    HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    摘要:
    公开号:
    EP3255042B1
  • 作为产物:
    描述:
    4-乙酰基哌啶-1-甲酸叔丁酯盐酸 作用下, 以 甲醇 为溶剂, 以85 %的产率得到1-(4-哌啶基)乙酮盐酸盐
    参考文献:
    名称:
    基于吡咯的系列 PfPKG 抗疟疾抑制剂的构效关系
    摘要:
    控制疟疾需要针对恶性疟原虫的新药。恶性疟原虫cGMP 依赖性蛋白激酶 (PfPKG) 是一个经过验证的靶标,其抑制剂可以阻断寄生虫生命周期的多个步骤。我们定义了抑制 PfPKG 的吡咯系列的构效关系 (SAR)。对关键药效基团进行了修改,以充分探索化学多样性并获得有关理想核心支架的知识。使用针对重组 PfPKG 和人 PKG 的体外效力来确定寄生虫酶的化合物选择性。使用伯氏疟原虫子孢子和恶性疟原虫无性血液阶段来测定多阶段抗寄生虫活性。使用表达带有取代的“看门人”残基的 PfPKG 的转基因寄生虫来评估化合物的细胞特异性。解析了与抑制剂结合的 PfPKG 的结构,并利用该结构与计算工具进行建模,以了解 SAR 并为后续先导化合物优化建立合理的策略。
    DOI:
    10.1021/acs.jmedchem.3c01795
点击查看最新优质反应信息

文献信息

  • [EN] RORGAMMA MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE RORGAMMA ET LEURS UTILISATIONS
    申请人:GENFIT
    公开号:WO2018138354A1
    公开(公告)日:2018-08-02
    The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases. (formula Ia)
    本发明提供了一种新型的化合物,其化学式为(Ia),这些化合物是RORgamma的调节剂。这些化合物以及包含它们的药物组合物是治疗任何疾病的合适手段,其中调节RORgamma具有治疗效果,例如在自身免疫疾病、自身免疫相关疾病、炎症性疾病、代谢性疾病、纤维化疾病或胆汁淤积性疾病中。
  • [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
    申请人:NOVIRA THERAPEUTICS INC
    公开号:WO2013096744A1
    公开(公告)日:2013-06-27
    The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    本发明包括一种抑制、压制或预防需要的人体内HBV感染的方法,包括向个体投给治疗有效量的至少一种本发明的化合物。
  • [EN] THERAPEUTIC METHODS AND COMPOUNDS<br/>[FR] PROCÉDÉS ET COMPOSÉS THÉRAPEUTIQUES
    申请人:UNIV RUTGERS
    公开号:WO2020219591A1
    公开(公告)日:2020-10-29
    The invention provides a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein R1-R5 Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful to treat malaria.
    该发明提供了一种化合物的公式I:(I)或其药用可接受的盐,其中R1-R5 Y具有规范中描述的任何值,以及包含公式I化合物的组合物。这些化合物可用于治疗疟疾。
  • Inhibition of serotonin reuptake
    申请人:Eli Lilly and Company
    公开号:US05846982A1
    公开(公告)日:1998-12-08
    This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.
    这项发明提供了一种用于抑制哺乳动物中5-羟色胺再摄取的化合物和方法。
  • 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake
    申请人:ELI LILLY AND COMPANY
    公开号:EP0812826A1
    公开(公告)日:1997-12-17
    The pharmaceutical use of novel compounds of formula I: where Z is a structure of formula A-B is -C=CH- or -C(R5)-CH2-; X is S or NR4; R1 is H, halo, formyl, C1-C4 alkyl, C1-C4 alkoxy, thienylmethyloxy, 4,5-dihydrothiazol-2-yl, cyano, nitro, carboxamido, trifluoromethyl or hydroxy; R2 is H or halo; R3 is H, C1-C4 alkyl, (C1-C4 alkylene)-aryl, or -CH2-Y-NR7R8; R4 is H, C1-C4 alkyl, C1-C5 acyl, or phenylsulfonyl; R5 is H or OH; R6 is H or methyl; Y is -CH2- or -C(O)-; R7 is pyridinyl; and R8 is H or -C(O)-(C3-C6 cycloalkyl); and pharmaceutically acceptable salts thereof.
    化合物的药用途:其中Z是formulaA-B结构,-C=CH-或-C(R5)-CH2-;X是S或NR4;R1是H、卤素、甲酰基、C1-C4烷基、C1-C4烷氧基、噻吩甲氧基、4,5-二氢噻唑-2-基、氰基、硝基、羧酰胺基、三氟甲基或羟基;R2是H或卤素;R3是H、C1-C4烷基、(C1-C4烷基)-芳基,或-CH2-Y-NR7R8;R4是H、C1-C4烷基、C1-C5酰基,或苯基磺酰基;R5是H或OH;R6是H或甲基;Y是-CH2-或-C(O)-;R7是吡啶基;R8是H或-C(O)-(C3-C6环烷基);以及其药用上可接受的盐。
查看更多